

2017/18 INTERIM RESULTS PRESENTATION



MEDICLINIC RESULTS DISCLAIMER

This presentation contains certain forward-looking statements relating to the financial condition, the regulatory environment in which we operate, results of operations and businesses of Mediclinic and the Group, including certain plans and objectives of the Group.

All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements.

Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow, production and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases.

MEDICLINIC RESULTS AGENDA

INTRODUCTION	Page 4
FINANCIAL REVIEW	Page 9
OPERATIONAL REVIEW	Page 21
SUMMARY AND OUTLOOK	Page 25
QUESTIONS AND ANSWERS	Page 27
APPENDIX	Page 28



INTRODUCTION

DANIE MEINTJES
CEO MEDICLINIC INTERNATIONAL




MEDICLINIC INTERNATIONAL

WHO WE ARE


WHAT	International private healthcare group	Over 30 years experience	Provide acute care, specialist-orientated, multi-disciplinary healthcare services
WHERE	Leading market positions in Switzerland, Southern Africa and the UAE	29.9% investment in UK-listed Spire Healthcare Group	Primary listed on the LSE; Secondary listed on the JSE and NSX
VISION	To be respected internationally and preferred locally		
PURPOSE	Enhance the quality of life of our patients by providing comprehensive, high-quality healthcare services		
STRATEGIC THEMES	Putting “Patients First” Offering a value proposition to our patients Improving quality, safety and efficiency	Continuing to grow Investing in our assets Investing in our employees	Create long-term shareholder value

MEDICLINIC INTERNATIONAL DIVERSIFIED GLOBAL FOOTPRINT


DISTRIBUTION OF THE GROUP'S
HOSPITALS




DISTRIBUTION OF THE GROUP'S
BEDS




DISTRIBUTION OF THE GROUP'S
EMPLOYEES




CONTRIBUTION TO GROUP
UNDERLYING REVENUE (£'M)



CONTRIBUTION TO GROUP
UNDERLYING EBITDA (£'M)



CONTRIBUTION TO GROUP
UNDERLYING EARNINGS (£'M)



■ Switzerland ■ Southern Africa ■ Middle East ■ UK ■ Corporate



MEDICLINIC INTERNATIONAL STRATEGIC THEMES

“PATIENTS FIRST” AT MEDICLINIC

- Superior clinical performance in a safe clinical environment
- Improved patient experience
- Integrated and coordinated care

IMPROVING EFFICIENCIES

- Improved operational effectiveness
 - Leverage combined international capacity through collaboration and shared resources
 - Pursue initiatives in operating platforms to improve operational efficiency
- Leveraged international Group benefits
 - Use central resources to achieve Group wide procurement efficiencies

INVESTING IN OUR ASSETS

- Focus on capital discipline and returns-orientated investments
- Increased capacity at existing infrastructure
- Acquisitive or organic growth in existing platforms
- Further international acquisitions






INVESTING IN OUR EMPLOYEES

- Identify, attract and retain leading specialists and talented healthcare professionals
- Improve employee engagement

Create long-term shareholder value

MEDICLINIC RESULTS HIGHLIGHTS

2017/18 GROUP INTERIM RESULTS

Revenue*	EBITDA*	Operating profit*	Cash conversion
 10% Flat in CC	 5%  5% in CC EBITDA* margin 16.5%	 3% EPS*  12%	91% of underlying EBITDA Interim dividend 3.20 pence per share maintained

* Underlying measures presented

Switzerland:	Patient volumes reflect Easter holiday period and subdued summer; lower margin
Southern Africa:	Patient volumes impacted by less working days and weak environment; maintained margin
Middle East:	Strong Dubai performance; positive trends in Abu Dhabi with growth in Thiqa patient volumes
Spire (UK):	Mediclinic underlying earnings impacted by a provision for litigation impacting Spire's reported earnings

FINANCIAL REVIEW

JURGENS MYBURGH
CFO MEDICLINIC INTERNATIONAL




UNDERLYING CONSOLIDATED INCOME STATEMENT

£'m	1H18	1H17	% CHANGE
Revenue	1,405	1,283	10%
EBITDA*	232	220	5%
<i>EBITDA* margin</i>	16.5%	17.1%	
Depreciation & Amortisation*	(71)	(63)	13%
Other gains and losses*	-	(1)	-
Operating profit*	161	156	3%
Net finance costs*	(39)	(39)	-
Taxation*	(29)	(26)	12%
Income from associates	1	10	(90%)
Non controlling interests	(10)	(7)	43%
Earnings*	84	94	(11%)
Earnings Per Share (pence)	11.3	12.8	(12%)
Interim dividend per share (pence)	3.20	3.20	-
<i>Weighted avg number of shares (m)</i>	737.1	736.9	

- Translational effect of currency
- Revenue growth reflects low patient volume in Southern Africa and Hirslanden and base effect in the Middle East
- EBITDA margin helped by cost savings
- Depreciation increase associated with ongoing investment in infrastructure
- Reduced Spire contribution reflects lower reported earnings due to litigation provision
- Normalised effective tax rate 24%
- Interim dividend of 3.20p maintained

GROUP REVENUE ANALYSIS



Hirslanden (46% of Group)

- Patient volumes impacted by Easter and subdued market during the summer
- Flat in constant currency, including Linde contribution

Southern Africa (32% of Group)


- Patient volumes impacted by nine fewer ordinary working days
- Weak macro-economic environment and funder interventions
- Up 4% in constant currency

Middle East (22% of Group)

- Strong revenue growth in Dubai offset by a decline in Abu Dhabi due to base effect
- Down 5% in constant currency

1H18 revenue increased 10% to £1,405m


REVENUE BRIDGE



- Hirslanden revenue flat in constant currency
- Constant currency revenue growth in Southern Africa and Dubai
- Abu Dhabi revenue shortfall:
 - Business and operational alignment
 - Regulatory changes
 - Non-core asset disposals
 - Increased competition

1H18 revenue flat in constant currency

UNDERLYING EBITDA ANALYSIS



Hirslanden (49% of Group)

- Patient volume impact and continued gradual shift in insurance mix
- Cost management initiatives implemented
- Down 6% in constant currency

Southern Africa (40% of Group)


- Patient volume impact more than offset by cost control measures
- Ongoing change in case mix due to outmigration
- Up 6% in constant currency

Middle East (12% of Group)

- Affected by revenue decline in Abu Dhabi
- Down 26% in constant currency

1H18 underlying EBITDA increased 5% to £232m

UNDERLYING EPS BRIDGE



* Mediclinic's investment in Spire is accounted for on an equity basis recognising the reported profit of GBP8.9m for the six months ended 30 June 2017 (2016: GBP35.7m). Spire's adjusted profit in the period was GBP34.7m (2016: GBP38.2m). The reported profit in the period was primarily impacted by a provision amounting to GBP27.6m for the potential cost of a settlement relating to civil litigation.

GROUP BALANCE SHEET SUMMARY

£'m	30 Sep 17	31 Mar 17
Assets	6,979	7,422
Non-current assets:		
Property, equipment and vehicles	3,661	3,703
Intangible assets	2,036	2,156
Other non-current assets	383	494
Current assets	899	1,069
Equity and liabilities	6,979	7,422
Shareholders' funds	3,849	4,086
Non-controlling interests	73	78
Interest-bearing debt	1,949	2,030
Other long-term liabilities	688	707
Current liabilities	420	521

- Currency impact
- Ongoing investment and Linde acquisition
- Spire impairment of £109m
- Successfully completed Hirslanden refinancing
- Responsible approach to leverage


GROUP CASH FLOW SUMMARY

£'m	1H18	1H17
Net cash flow from operating activities	149	176
Cash flow from investment activities	(182)	(104)
Investment to maintain operations	(62)	(45)
Investment to expand operations	(57)	(53)
Business combinations	(83)	-
Other	20	(6)
Cash flow from financing activities	(48)	(124)
Distributions to non-controlling interests	(8)	(7)
Distributions to shareholders	(35)	(45)
Borrowings and other	(5)	(72)
Net increase/(decrease) in cash and cash equivalents	(81)	(52)
Closing balance of cash and cash equivalents	262	262
Net debt	(1,687)	(1,768)


- Strong cash flow generation across all platforms impacted by timing of payables
- 91% cash conversion
- Linde acquisition funded through available cash

GROUP CAPITAL EXPENDITURE

**TOTAL CAPITAL
EXPENDITURE
FY17 (£'m)**



**BUDGETED CAPITAL
EXPENDITURE
FY18 (£'m)***



- Revised FY18 capex budget 12% lower in constant currency compared to original budget:
 - Adapting Hirslanden capex plans to reflect current business environment
 - Matlosana Competition Commission delays now reflected in MCSA
 - MCME capex growth related to expansion; timing differences lowering budgeted spend in FY18
- FY18 capex spend weighted to the second half of the year across all platforms

*Constant currency basis:
GBP/CHF: 1.29
GBP/ZAR: 18.41
GBP/AED: 4.80

Focus on capital discipline and returns-orientated investment across the Group

** Excludes £83m associated with acquisitions in Switzerland

HIRSLANDEN

FINANCIAL OVERVIEW

CHF'm	1H18	1H17	% CHANGE
Revenue*	820	819	-
EBITDA*	143	152	(6%)
<i>EBITDA* margin</i>	17.4%	18.6%	
Depreciation & Amortisation	(52)	(48)	10%
Operating profit*	90	105	(14%)
Net finance costs* ^Δ	(35)	(37)	(7%)
Income tax expense	(12)	(14)	(14%)
<i>Effective tax rate</i>	21.5%	21.0%	
Earnings* ^Δ	44	54	(19%)
Movement in bed days sold	(1.9%)	(0.1%)	
Movement in revenue per bed day	(0.1%)	3.3%	
Inpatients (000's)	48	48	(1.3%)

- Revenue impacted by lower patient volumes due to timing of Easter and subdued market during the summer, partially offset by contribution from Linde acquisition
- Outpatient strategy yielding positive results with 6% revenue growth
- EBITDA* margin impacted by lower revenues; cost-management and efficiency measures implemented
- Cash conversion 91% (1H17: 113%)
- Capex totalled CHF41m
- Borrowings increased by CHF37m

* Underlying measures presented

^Δ Includes inter-company loan interest which is eliminated in the Group earnings reconciliation

MEDICLINIC SOUTHERN AFRICA

FINANCIAL OVERVIEW

ZAR'm	1H18	1H17	% CHANGE
Revenue	7,581	7,283	4%
EBITDA*	1,590	1,506	6%
<i>EBITDA* margin</i>	21.0%	20.7%	
Depreciation & Amortisation	(253)	(219)	16%
Operating profit*	1,338	1,287	4%
Net finance costs	(266)	(233)	14%
Income tax expense	(331)	(320)	3%
<i>Effective tax rate</i>	31.0%	30.3%	
Non-controlling interests	(150)	(139)	8%
Earnings*	589	596	(1%)
Movement in bed days sold	(3.3%)	2.6%	
Movement in revenue per bed day	7.7%	5.5%	
Admissions (000's)	289	299	(3.3)%

* Underlying measures presented

- Revenue growth affected by lower patient volumes:
 - 9 fewer ordinary working days
 - Weak macro environment
 - Funder interventions
 - Increased competition
- Revenue per bed day increase related to inflation and mix change
- EBITDA* margin supported by a focus on cost-management
- D&A increase due to prior year adjustment in residual value
- Cash conversion 88% (1H17: 94%)
- Capex totalled ZAR460m
- Borrowings flat

MEDICLINIC MIDDLE EAST FINANCIAL OVERVIEW

AED'm	1H18	1H17	% CHANGE
Revenue	1,475	1,547	(5%)
EBITDA*	125	170	(26%)
<i>EBITDA* margin</i>	8.5%	11.0%	
Depreciation & Amortisation*	(74)	(82)	(10%)
Operating profit*	52	88	(41%)
Net finance costs	(17)	(13)	27%
Non-controlling interest	(4)	1	
Earnings*	31	76	(59%)
Movement in bed days sold	(7.8%)	3.1%**	
Inpatients ('000s)	33	34	(2.2%)
Outpatients ('000s)	1,356	1,592	(14.8%)

* Underlying measures presented

** Compared to 1H16 pro forma data

- Strong revenue growth in Dubai up 7%; Abu Dhabi impacted by base effect
- Quality of revenue improving due to business and operational alignment initiatives in Abu Dhabi:
 - Thiqa inpatients up 40%
 - Thiqa outpatients up 15%
- Depreciation increased due to ongoing investment
- Al Noor brand name amortisation accelerated, eliminating normal amortisation in 1H18
- Cash conversion 91% (1H17: 100%)
- Capex totalled AED133m
- Borrowings decreased by AED43m

OPERATIONAL REVIEW

DANIE MEINTJES
CEO MEDICLINIC INTERNATIONAL





OPERATIONS HIRSLANDEN


OPERATIONS

- ⚙️ Largest Swiss private hospital group; competitive mature healthcare market; delivering exceptional quality clinical care to wealthy ageing population
- ⚙️ Focused on driving efficiencies and investing for future growth
- ⚙️ Hirslanden 2020 strategic programme:
 - Standardise and centralise processes
 - Outpatient facilities
- ⚙️ Acquired 115-bed Linde hospital in Biel
- ⚙️ Continued change in insurance mix
- ⚙️ Implementation of national TARMED outpatient tariff reductions from 1 Jan 2018
- ⚙️ Preparing a national framework for the outmigration of basic medical treatments

OPERATIONAL OVERVIEW



BED NUMBERS AND OCCUPANCY





OPERATIONS SOUTHERN AFRICA


OPERATIONS

- Mediclinic maintains its leading market position with eight hospitals featured in Discovery Health's top 20 private hospitals
- Stable medical scheme membership offset by ageing population and increase in chronic diseases
- Challenging macro-environment persists putting pressure on patients and funders
- Inpatient admissions affected by outmigration of day cases and ongoing shift from surgical to medical
- Rolling out 5 further day clinics
- Health Market Inquiry and National Health Insurance review both ongoing

OPERATIONAL OVERVIEW



BED NUMBERS AND OCCUPANCY





OPERATIONS MIDDLE EAST


OPERATIONS

- Well positioned to benefit from long-term growth opportunities in the UAE; building on our leading market position in Dubai
- Actions taken in Abu Dhabi have set the foundations for future growth; positive trends building; Al Jowhara performing well
- Investing in doctors, services and technology, new hospitals, expansion and upgrade projects and rebranding; divested several non-core assets
- Supporting new doctor to ramp up activity; focused on new insurance mix and tariff strategy
- Mediclinic's new Parkview Hospital and projects at Airport Road and Al Noor hospitals all on track; Western Region Hospital project reinstated

OPERATIONAL OVERVIEW



ABU DHABI PATIENT MIX



SUMMARY AND OUTLOOK

DANIE MEINTJES
CEO MEDICLINIC INTERNATIONAL

MEDICLINIC INTERNATIONAL

SUMMARY AND OUTLOOK

- Well positioned to deliver long-term value to shareholders
- Market leading positions in all three operating divisions
- Deliver high-quality care focusing on “Patients First” strategy
- Focus on efficiencies to maintain affordability of healthcare
- Consider new business opportunities and care delivery models
- Continue to invest in our people, facilities and services
- Current trading in the second half of the year across all operating divisions is in line with expectations; guidance remains unchanged

**LONG-TERM DEMAND FOR PRIVATE HEALTHCARE REMAINS ROBUST;
UNDERPINNED BY AN AGEING POPULATION, GROWING DISEASE BURDEN AND
TECHNOLOGICAL INNOVATION**

QUESTIONS AND ANSWERS

James Arnold

Head of Investor Relations
MEDICLINIC INTERNATIONAL PLC

14 Curzon Street
London
W1J 5HN
United Kingdom
Tel: +44 (0) 20 3786 8181
James.Arnold@Mediclinic.com
www.mediclinic.com



APPENDIX



MEDICLINIC INTERNATIONAL

FY18 GUIDANCE

HIRSLANDEN

- Modest revenue growth given already high occupancy rates, stable beds and the impact of two Easter periods
- Underlying EBITDA margin in second half FY18 will typically reflect the seasonal benefit of the winter period including higher occupancy and improved insurance mix
- Full year margin impacted by TARMED tariff reductions from 1 Jan 2018, outmigration, two Easter periods, costs relating to the Hirslanden 2020 strategic programme and the Linde acquisition, partially offset by ongoing efficiency gains

MEDICLINIC SOUTHERN AFRICA

- Revenue growth around 4% due to challenging macro-economic environment, greater competition, funder interventions and two Easter periods
- Broadly stable underlying EBITDA margin at 21%

MEDICLINIC MIDDLE EAST

- Dubai: Continues to perform well despite the competitive landscape
- Abu Dhabi: Gradual improvement over the next couple of years
- Strong revenue and underlying EBITDA growth in the second half FY18
- Marginal improvement in full year revenue
- Gradual improvement in underlying EBITDA margins over time, including the impact associated with opening new facilities from FY19

Current trading across all platforms in line with expectations

FOREIGN EXCHANGE RATES

Average rates	1H18	1H17	% CHANGE
GBP/CHF	1.26	1.34	(6%)
GBP/ZAR	17.08	20.00	(15%)
GBP/AED	4.75	5.05	(6%)

Closing rates	1H18	FY17	% CHANGE
GBP/CHF	1.30	1.25	4%
GBP/ZAR	18.08	16.74	8%
GBP/AED	4.92	4.59	7%



GROUP DEBT STRUCTURE

30 SEPTEMBER 2017

MEDICLINIC SOUTHERN AFRICA	Carrying value ZARm	Carrying value £'m	Terms	Date repayable
Senior term	4,179	230	3M Jibar +1.51% (ZAR 2,971m) and +1.69% (ZAR1,208m)	3 Jun 2019
Preference shares	3,315	184	Prime x 69% and 73%	Jun 2019 and 2020
Senior amortising	110	6	3M Jibar +1.06%	9 Oct 2017
Subsidiaries	91	5	Prime interest rate	1 to 12 years
Capex facility	504	28	3M Jibar +1.51%	3 Jun 2019
Total debt	8,197	453		
Interest expense	355	20		
HIRSLANDEN	Carrying value CHFm	Carrying value £'m	Terms	Date repayable
Secured long-term bank loans	1,507	1,160	CHF 1450m Swiss 3M Libor +1.5%, CHF 100m Swiss Libor +2.85%	31 Jul 2020
Swiss bonds	235	181	CHF 145m at 6 year 1.625%, CHF90m at 10 year 2.0%	Feb 2021 & 2025
Secured long-term finance	3	2	Interest ranging between 1.26 to 12.0%	1 to 7 years
Total debt	1,745	1,343		
Interest expense	21	17		
MEDICLINIC MIDDLE EAST	Carrying value AEDm	Carrying value £'m	Terms	Date repayable
Bank loans	750	153	3M Libor +2.75%	Jun 2020 & May 2021
Total debt	750	153		
Interest expense	18	4		
Total Group interest expense		41		
TOTAL GROUP DEBT (£'m)		1,949		
CASH AND CASH EQUIVALENTS (£'m)		(262)		
GROUP NET DEBT (£'m)		1,687		

GROUP CAPITAL EXPENDITURE

FY17 Actual capex (£'m)	Hirslanden	Southern Africa	Middle East	Total
To maintain operations	69	28	12	109
To expand operations	57	43	40	140
Total capital expenditure	126	71	52	249

1H18 Actual capex (£'m)*	Hirslanden	Southern Africa	Middle East	Total
To maintain operations	20	14	6	39
To expand operations	12	13	22	46
Total capital expenditure	32	27	28	87



FY18 Budgeted capex (£'m)*	Hirslanden	Southern Africa	Middle East	Total
To maintain operations	62	19	16	97
To expand operations	52	45	53	150
Total capital expenditure	114	64	69	247

- Capex second half weighted across all platforms
- MCME: Increase in FY18 expansion capex largely related to Mediclinic Parkview Hospital and EHR projects
- MCSA: Gradual expansion programme continues; excludes Matlosana awaiting Competition Tribunal approval


* Constant currency basis: GBP/CHF: 1.29, GBP/ZAR: 18.41, GBP/AED: 4.80

FIVE YEAR OPERATIONAL SUMMARY

HIRSLANDEN



SOUTHERN AFRICA





OPERATIONS HIRSLANDEN (SWITZERLAND)

OVERVIEW



HOSPITALS
17





CLINICS
4



BEDS
1,792



EMPLOYEES
9,881



DR OLE WIESINGER
CEO HIRSLANDEN



FLAGSHIP HOSPITAL HIRSLANDEN (SWITZERLAND)



KLINIK HIRSLANDEN – ZÜRICH



TOTAL BEDS

330

THEATRES

14 Incl. 1 hybrid

EMPLOYEES

c.1,800

ICU BEDS

20

MEDICAL DOCTORS

c.500



CAPITAL PROJECTS HIRSLANDEN

CAPITAL PROJECTS DURING 1H18

Hospital	Project	Completion
Klinik St. Anna	MRI 3 Tesla	1H18
Klinik St. Anna	O-arm® Surgical Imaging system	1H18
Klinik Im Park	Outpatient surgery unit "Bellaria"	1H18

FUTURE PROJECTS

Hospital	Project	Expected Completion
Klinik Hirslanden	Capacity expansion; gastroenterology & stroke unit	2H18
Salemspital	PETCT	2H18
Klinik Permanence	Radiology institute "Cosmos"	2H18
Salemspital	PETCT	2H18
Klinik Stephanshorn	DaVinci robot	2H18
Klinik Stephanshorn	Restructuring of entrance	2H18
Klinik Birshof	O-arm® Surgical Imaging system	2H18
Klinik Hirslanden	HKL 1 Biplane	FY19
Klinik Hirslanden	Emergency practice with 8 beds	FY19
Klinik Im Park (Kappelistrasse)	Medical centre, breast centre, extension radiology	FY19
AndreasKlinik (Cham Lorze)	Doctor's offices	FY19
Klinik Birshof	IMC/physicians house	FY19
Clinique La Colline	Sport medicine centre	FY19
Klinik Stephanshorn (Schuppis)	Doctor's offices	FY19
Klinik Hirslanden (Seefeldstrasse)	Doctor's offices	FY19
Klinik St. Anna	Ward C5 with 12 beds	FY19
Klinik Linde	Extension of emergency unit, radiology	FY19
Klinik Im Park	Renovation of 3 rd floor	FY 20



OVERVIEW



HOSPITALS

52



DAY CLINICS

2





BEDS

8,095



EMPLOYEES

16,366



KOERT PRETORIUS
CEO MEDICLINIC SOUTHERN AFRICA



FLAGSHIP HOSPITAL SOUTHERN AFRICA



MEDICLINIC BLOEMFONTEIN



THEATRES	CATH LABS	PET	TOTAL BEDS	MRI'S	ICU BEDS	CONSULTANTS
12	2	1	383	2	75	70 Admitting



CAPITAL PROJECTS SOUTHERN AFRICA

CAPITAL PROJECTS DURING 1H18

Hospital	Completion	Licenced Beds
<i>Growth into existing license</i>		
Mediclinic Bloemfontein (12 additional operational beds)	1H18	-
Total licenced beds	As at 1H18	8,095

FUTURE PROJECTS*

Hospital	Expected Completion	Beds
<i>Existing hospitals</i>		
Mediclinic Thabazimbi	2H18	12
Mediclinic Newcastle	2H18	30
Mediclinic Stellenbosch	1H20	50
Mediclinic Legae	1H20	23
Mediclinic Vergelegen	1H20	28
Mediclinic Cape Gate	2H20	13
Mediclinic Potchefstroom	2H20	70
Mediclinic Medforum	2H20	23
<i>Day clinics</i>		
Mediclinic Newcastle Day Clinic	1H19	30 (3 theatres)
Mediclinic Nelspruit Day Clinic	1H20	20 (2 theatres)
Mediclinic Stellenbosch Day Clinic	1H20	20 (2 theatres)
Mediclinic Bloemfontein Day Clinic (awaiting license)	2H20	33 (3 theatres)
Mediclinic Cape Gate Day Clinic	2H20	20 (2 theatres)
<i>Additional/new facilities</i>		
Klerksdorp	Awaiting Competition Tribunal Hearing (May 2018)	256
Intercare	Completed DD – requires CC approval	
- Day clinics		92
- Sub-acute		128

**Subject to DOH Approval*



OPERATIONS

MEDICLINIC MIDDLE EAST

OVERVIEW



HOSPITALS
6




DAY CLINICS
24



BEDS
714



EMPLOYEES
5,884



DAVID HADLEY
CEO MEDICLINIC MIDDLE EAST



FLAGSHIP HOSPITALS

MEDICLINIC MIDDLE EAST

MEDICLINIC CITY HOSPITAL - DUBAI



**TOTAL
BEDS**
279

**OPERATING
THEATRES**
5

**PEADIATRIC ICU
BEDS**
6

**CATH
LAB**
1

NEW NORTH WING



**ICU
BEDS**
15

MRI
2

**NEONATAL ICU
BEDS**
27

CT
1



FLAGSHIP HOSPITALS

MEDICLINIC MIDDLE EAST



MEDICLINIC AIRPORT ROAD – ABU DHABI



HOSPITAL EXPANSION & Cancer Centre	PROJECT COMPLETION Q4 FY19	NEONATAL ICU BEDS 14	TOTAL BEDS 136	CT 1	MRI 1	HIGH DEPENDANCY UNIT BEDS 10
OPERATING THEATRES 4	TOTAL ICU BEDS 16	CATH LAB 1				



CAPITAL PROJECTS DUBAI

MEDICLINIC PARKVIEW HOSPITAL



BUDGET	TOTAL BEDS	PROJECT COMPLETION	ICU BEDS	CONSULTATION ROOMS	ER BEDS	NEONATAL ICU BEDS	CATH LAB	OPERATING THEATRES
AED680m	188	Q4 FY19	15	100	19	22	1	5

SPIRE HEALTHCARE GROUP PLC

UNITED KINGDOM

- Mediclinic's 29.9% investment in Spire gives the Group exposure to UK private healthcare market
- Spire is ideally positioned to be a leading player in the independent hospital sector given its scale, reach and quality of care
- Underlying performance in the first half of 2017 was positive and in line with expectations
- Reported earnings impacted by a £27.6m provision relating to civil litigation against a consultant who previously had practicing privileges at Spire Healthcare
- Total inpatient/day case admissions grew 0.3%
- New build hospital at Milton Keynes underway
- Management revised its outlook for FY2017 due to significantly lower than anticipated revenues in Jul/Aug 2017 primarily related to a decline in NHS e-referral activity

